Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis

James H. Tabibian, Andrea Gossard, Mounif El-Youssef, John E. Eaton, Jan Petz, Roberta Jorgensen, Felicity B. Enders, Anilga Tabibian, Keith D. Lindor

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease in which emerging data suggest that oral antibiotics may offer therapeutic effects. We enrolled patients with PSC in a 12-week, open-label pilot study to investigate the efficacy and safety of 550 mg of oral rifaximin twice daily. The primary end point was serum alkaline phosphatase (ALK) at 12 weeks. Secondary end points included (1) serum bilirubin, gamma-glutamyl transpeptidase, and Mayo PSC risk score; (2) fatigue impact scale, chronic liver disease questionnaire, and short form health survey (SF-36) scores; and (3) adverse effects (AEs). Analyses were performed with nonparametric tests. Sixteen patients were enrolled, among whom the median age was 40 years; 13 (81%) were male, 13 had inflammatory bowel disease, and baseline ALK was 342 IU/mL (interquartile range, 275-520 IU/mL). After 12 weeks of treatment, there were no significant changes in ALK (median increase of 0.9% to 345 IU/mL; P = 0.47) or any of the secondary biochemical end points (all P > 0.05). Similarly, there were no significant changes in fatigue impact scale, chronic liver disease questionnaire, or SF-36 scores (all P > 0.05). Three patients withdrew from the study due to AEs; 4 others reported mild AEs but completed the study. In conclusion, although some antibiotics may have promise in treating PSC, oral rifaximin, based on the results herein, seems inefficacious for this indication. Future studies are needed to understand how the antimicrobial spectra and other properties of antibiotics might determine their utility in treating PSC.

Original languageEnglish (US)
Pages (from-to)e56-e63
JournalAmerican Journal of Therapeutics
Volume24
Issue number1
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

rifaximin
Sclerosing Cholangitis
Clinical Trials
Alkaline Phosphatase
Liver Diseases
Anti-Bacterial Agents
Fatigue
Chronic Disease
Therapeutics
gamma-Glutamyltransferase
Therapeutic Uses
Health Surveys
Serum
Bilirubin
Safety

Keywords

  • Biliary tract disease
  • Cholangiocyte
  • Enterohepatic circulation
  • Fibrosis
  • Translational medical research

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Tabibian, J. H., Gossard, A., El-Youssef, M., Eaton, J. E., Petz, J., Jorgensen, R., ... Lindor, K. D. (2017). Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis. American Journal of Therapeutics, 24(1), e56-e63. https://doi.org/10.1097/MJT.0000000000000102

Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis. / Tabibian, James H.; Gossard, Andrea; El-Youssef, Mounif; Eaton, John E.; Petz, Jan; Jorgensen, Roberta; Enders, Felicity B.; Tabibian, Anilga; Lindor, Keith D.

In: American Journal of Therapeutics, Vol. 24, No. 1, 2017, p. e56-e63.

Research output: Contribution to journalArticle

Tabibian, JH, Gossard, A, El-Youssef, M, Eaton, JE, Petz, J, Jorgensen, R, Enders, FB, Tabibian, A & Lindor, KD 2017, 'Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis', American Journal of Therapeutics, vol. 24, no. 1, pp. e56-e63. https://doi.org/10.1097/MJT.0000000000000102
Tabibian, James H. ; Gossard, Andrea ; El-Youssef, Mounif ; Eaton, John E. ; Petz, Jan ; Jorgensen, Roberta ; Enders, Felicity B. ; Tabibian, Anilga ; Lindor, Keith D. / Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis. In: American Journal of Therapeutics. 2017 ; Vol. 24, No. 1. pp. e56-e63.
@article{a94e340017bd4fcdb2cfd08bab0eef39,
title = "Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease in which emerging data suggest that oral antibiotics may offer therapeutic effects. We enrolled patients with PSC in a 12-week, open-label pilot study to investigate the efficacy and safety of 550 mg of oral rifaximin twice daily. The primary end point was serum alkaline phosphatase (ALK) at 12 weeks. Secondary end points included (1) serum bilirubin, gamma-glutamyl transpeptidase, and Mayo PSC risk score; (2) fatigue impact scale, chronic liver disease questionnaire, and short form health survey (SF-36) scores; and (3) adverse effects (AEs). Analyses were performed with nonparametric tests. Sixteen patients were enrolled, among whom the median age was 40 years; 13 (81{\%}) were male, 13 had inflammatory bowel disease, and baseline ALK was 342 IU/mL (interquartile range, 275-520 IU/mL). After 12 weeks of treatment, there were no significant changes in ALK (median increase of 0.9{\%} to 345 IU/mL; P = 0.47) or any of the secondary biochemical end points (all P > 0.05). Similarly, there were no significant changes in fatigue impact scale, chronic liver disease questionnaire, or SF-36 scores (all P > 0.05). Three patients withdrew from the study due to AEs; 4 others reported mild AEs but completed the study. In conclusion, although some antibiotics may have promise in treating PSC, oral rifaximin, based on the results herein, seems inefficacious for this indication. Future studies are needed to understand how the antimicrobial spectra and other properties of antibiotics might determine their utility in treating PSC.",
keywords = "Biliary tract disease, Cholangiocyte, Enterohepatic circulation, Fibrosis, Translational medical research",
author = "Tabibian, {James H.} and Andrea Gossard and Mounif El-Youssef and Eaton, {John E.} and Jan Petz and Roberta Jorgensen and Enders, {Felicity B.} and Anilga Tabibian and Lindor, {Keith D.}",
year = "2017",
doi = "10.1097/MJT.0000000000000102",
language = "English (US)",
volume = "24",
pages = "e56--e63",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis

AU - Tabibian, James H.

AU - Gossard, Andrea

AU - El-Youssef, Mounif

AU - Eaton, John E.

AU - Petz, Jan

AU - Jorgensen, Roberta

AU - Enders, Felicity B.

AU - Tabibian, Anilga

AU - Lindor, Keith D.

PY - 2017

Y1 - 2017

N2 - Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease in which emerging data suggest that oral antibiotics may offer therapeutic effects. We enrolled patients with PSC in a 12-week, open-label pilot study to investigate the efficacy and safety of 550 mg of oral rifaximin twice daily. The primary end point was serum alkaline phosphatase (ALK) at 12 weeks. Secondary end points included (1) serum bilirubin, gamma-glutamyl transpeptidase, and Mayo PSC risk score; (2) fatigue impact scale, chronic liver disease questionnaire, and short form health survey (SF-36) scores; and (3) adverse effects (AEs). Analyses were performed with nonparametric tests. Sixteen patients were enrolled, among whom the median age was 40 years; 13 (81%) were male, 13 had inflammatory bowel disease, and baseline ALK was 342 IU/mL (interquartile range, 275-520 IU/mL). After 12 weeks of treatment, there were no significant changes in ALK (median increase of 0.9% to 345 IU/mL; P = 0.47) or any of the secondary biochemical end points (all P > 0.05). Similarly, there were no significant changes in fatigue impact scale, chronic liver disease questionnaire, or SF-36 scores (all P > 0.05). Three patients withdrew from the study due to AEs; 4 others reported mild AEs but completed the study. In conclusion, although some antibiotics may have promise in treating PSC, oral rifaximin, based on the results herein, seems inefficacious for this indication. Future studies are needed to understand how the antimicrobial spectra and other properties of antibiotics might determine their utility in treating PSC.

AB - Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease in which emerging data suggest that oral antibiotics may offer therapeutic effects. We enrolled patients with PSC in a 12-week, open-label pilot study to investigate the efficacy and safety of 550 mg of oral rifaximin twice daily. The primary end point was serum alkaline phosphatase (ALK) at 12 weeks. Secondary end points included (1) serum bilirubin, gamma-glutamyl transpeptidase, and Mayo PSC risk score; (2) fatigue impact scale, chronic liver disease questionnaire, and short form health survey (SF-36) scores; and (3) adverse effects (AEs). Analyses were performed with nonparametric tests. Sixteen patients were enrolled, among whom the median age was 40 years; 13 (81%) were male, 13 had inflammatory bowel disease, and baseline ALK was 342 IU/mL (interquartile range, 275-520 IU/mL). After 12 weeks of treatment, there were no significant changes in ALK (median increase of 0.9% to 345 IU/mL; P = 0.47) or any of the secondary biochemical end points (all P > 0.05). Similarly, there were no significant changes in fatigue impact scale, chronic liver disease questionnaire, or SF-36 scores (all P > 0.05). Three patients withdrew from the study due to AEs; 4 others reported mild AEs but completed the study. In conclusion, although some antibiotics may have promise in treating PSC, oral rifaximin, based on the results herein, seems inefficacious for this indication. Future studies are needed to understand how the antimicrobial spectra and other properties of antibiotics might determine their utility in treating PSC.

KW - Biliary tract disease

KW - Cholangiocyte

KW - Enterohepatic circulation

KW - Fibrosis

KW - Translational medical research

UR - http://www.scopus.com/inward/record.url?scp=84901863080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901863080&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000102

DO - 10.1097/MJT.0000000000000102

M3 - Article

C2 - 24914504

AN - SCOPUS:84901863080

VL - 24

SP - e56-e63

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -